Anatara Lifesciences Ltd (AU:ANR) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Anatara Lifesciences is advancing its Phase II trial for GaRP in treating Irritable Bowel Syndrome and has introduced a new anti-obesity project aimed at creating an oral medication for weight management. The company has successfully raised capital through a placement to sophisticated investors, demonstrating its commitment to enhancing shareholder value and expanding its human health portfolio.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.